Jason M. Hafron, director of research at the Michigan Institute of Urology, was taken aback by the results of a study he was conducting: the vast majority of patients with prostate cancer who need regular injections to suppress their testosterone levels didn't get treated on time.
![Conversation with The Cancer Letter](https://cdn.cancerletter.com/media/2020/11/18170519/qa-300x300.jpg)
![Conversation with The Cancer Letter](https://cdn.cancerletter.com/media/2020/11/18170519/qa-300x300.jpg)